Press Releases BioSenic SA

Equities

BIOS

BE0974280126

Real-time Euronext Bruxelles Other stock markets 02:59:07 03/05/2024 pm IST			5-day change	1st Jan Change
0.0136 ^EUR	-4.23%		-30.61%	-77.78%

11/04	Biosenic: launch of a debt restructuring plan	CF
12/03	Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles	26/04	GL
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023	24/04	GL
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023	24/04	AQ
BioSenic S.A. : Transparency notifications received from François Rieger	18/04	GL
BioSenic provides further information on its restructuring plan	12/04	GL
BioSenic : summary bonds refinancing_20240411	12/04	PU
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	11/04	GL
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	11/04	AQ
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress	20/03	GL
BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease	12/03	GL
BioSenic raises €500,000 in private placement of new shares with established new investors	02/02	GL
BioSenic provides support to forthcoming European conference on graft-versus-host disease	31/01	GL
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform	30/01	GL
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress	25/01	GL
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress	25/01	AQ
BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis	23/01	GL
BioSenic S.A. : Transparency notifications received from François Rieger	15/01	GL
BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment	15/01	GL
BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer	10/01	GL
BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer	10/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioSenic SA

Equities

BIOS

BE0974280126

Press Releases

Filters